phrykt

EyePoint, Inc. (EYPT): who owns it and who trades it

As of Nov 16, 2026, EYPT insiders reported 10 open-market sales worth $2M and 2 purchases worth $72K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Cormorant Asset Management, LP (Other), with $942K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling EyePoint

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns EYPT

188 funds and institutions reported EYPT shares worth $1.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 9.9%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Montanova Capital, LLC9.9%
BlackRock, Inc.8.9%
Cormorant Asset Management, LP8.3%
Federated Hermes, Inc.6.8%
Adage Capital Partners Gp, L.l.c.5.8%
Franklin Resources Inc5.7%
Commodore Capital LP5.5%
Jupiter Topco LLC4.5%
Vanguard Capital Management LLC4.3%
Paradigm Biocapital Advisors LP3.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Montanova Capital, LLC8.30M9.90%$119MNo change
BlackRock, Inc.7.46M8.90%$107M+4%
Cormorant Asset Management, LP7.00M8.35%$100M-15%
Federated Hermes, Inc.5.68M6.78%$81.2M+0%
Adage Capital Partners Gp, L.l.c.4.83M5.76%$69M+46%
Franklin Resources Inc4.81M5.73%$68.7M-5%
Commodore Capital LP4.60M5.49%$65.8M+63%
Jupiter Topco LLC3.77M4.50%$53.9M–
Vanguard Capital Management LLC3.63M4.33%$51.9M+2%
Paradigm Biocapital Advisors LP2.89M3.45%$41.3M-8%
State Street Corp2.36M2.81%$33.7M+12%
Geode Capital Management, LLC2.06M2.46%$29.5M+4%
Aberdeen Group plc2.01M2.40%$28.7M+16%
Citadel Advisors LLC1.98M2.36%$28.3M+4%
Balyasny Asset Management L.P.1.81M2.16%$25.9M+26%
Parkman Healthcare Partners LLC1.29M1.54%$18.4M-5%
Eventide Asset Management, LLC1.25M1.49%$17.8MNo change
Two Sigma Investments, LP1.18M1.41%$16.9M+174%
Essex Woodlands Management, Inc.1.08M1.29%$15.5MNo change
Orbimed Advisors LLC1.07M1.28%$15.3MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, EYPT insiders reported $72K of open-market purchases and $2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$72K
2 trades, 2 people
Sales, 12 months
$2M
10 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 18, 2026
Filed Aug 18, 2026

Purchases and sales by month

$1.1M$1.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 18, 2026Karen L. ZaderejDirectorPurchase10,600$4.93$52.3KForm 4
Jun 30, 2026Ramiro RibeiroChief Medical OfficerSale2,438$15.02$36.6KForm 4
Jun 30, 2026Ramiro RibeiroChief Medical OfficerSale2,437$15.00$36.6KForm 4
Apr 17, 2026Ramiro RibeiroChief Medical OfficerSale2,437$15.00$36.6KForm 4
Mar 16, 2026Jay S. DukerCEOPurchase1,500$13.15$19.7KForm 4
Mar 4, 2026Ramiro RibeiroChief Medical OfficerSale2,438$17.87$43.6KForm 4
Feb 17, 2026Ramiro RibeiroChief Medical OfficerSale2,437$15.00$36.6KForm 4
Jan 5, 2026Ramiro RibeiroChief Medical OfficerSale42,544$17.10$728KForm 4
Dec 4, 2025Cormorant Asset Management, LP +2OtherSale60,000$15.70$942KForm 4
Dec 4, 2025Nancy LurkerDirectorSale9,300$15.11$141KForm 4
Nov 28, 2025Nancy LurkerDirectorSale500$14.95$7.5KForm 4
Nov 26, 2025Nancy LurkerDirectorSale200$14.95$3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Cormorant Asset Management, LPOther–$942KDec 4, 2025
Ramiro RibeiroChief Medical Officer–$917KJun 30, 2026
Nancy LurkerDirector–$151KDec 4, 2025
Karen L. ZaderejDirector$52.3K–Aug 18, 2026
Jay S. DukerPresident and CEO, Director$19.7K–Mar 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

EYPT short interest

High short interest. 12.8% of EYPT shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 22%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.02M EYPT shares were sold short, 12.8% of the shares outstanding, down 48.2% from the report before. At the average daily volume of 29.80M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

12.8%May 15Oct 3026.4%

Days to cover

1.0May 15Oct 3019.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.02M12.78%-48%29.80M1.0
Oct 15, 202621.26M24.66%+2%2.63M8.1
Sep 30, 202620.79M24.11%+5%3.86M5.4
Sep 15, 202619.81M22.98%+9%3.08M6.4
Aug 31, 202618.11M21.01%-2%10.51M1.7
Aug 14, 202618.43M21.37%+2%2.02M9.1
Jul 31, 202618.02M20.90%+10%1.46M12.3
Jul 15, 202616.43M19.59%+9%1.59M10.3
Jun 30, 202615.11M18.03%+0%1.57M9.6
Jun 15, 202615.08M17.98%-0%1.09M13.8
May 29, 202615.10M18.01%+7%1.00M15.1
May 15, 202614.15M16.88%-0%838,59516.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

EyePoint company events

EyePoint filed 17 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 19, 2026.

  1. Oct 19, 2026AnnouncementThe Company issued a press release announcing the Prioritization. Filing
  2. Oct 19, 2026AnnouncementEyePoint, Inc. issued a press release announcing topline data for LUCIA, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD). Filing
  3. Sep 10, 2026AnnouncementEyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio. Filing
  4. Aug 17, 2026AnnouncementEyePoint, Inc. issued a press release announcing topline data for LUGANO, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD). Filing
  5. Aug 5, 2026ResultsReleased financial results. Filing
  6. Jul 30, 2026AnnouncementEyePoint, Inc. issued a press release announcing it has completed enrollment in the pivotal Phase 3 clinical trials evaluating DURAVYU™ for the treatment of diabetic macular edema. Filing
  7. Jul 17, 2026AgreementEyePoint, Inc. entered into a settlement agreement with the United States of America, acting through the U.S. Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services and the Defense Health Agency, acting on behalf of the TRICARE Program… Filing
  8. Jun 22, 2026LeadershipEyePoint, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026 via live webcast. Filing
  9. May 14, 2026AnnouncementEyePoint, Inc. issued a press release announcing a positive recommendation from the independent Data Safety Monitoring Committee following completion of its third scheduled review of the Company’s ongoing pivotal Phase 3 program evaluating DURAVYU ™ for the treatment of wet age-related macular… Filing
  10. May 6, 2026ResultsReleased financial results. Filing
  11. Apr 13, 2026AnnouncementEyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio. Filing
  12. Mar 20, 2026AnnouncementShared information with investors. Filing
  13. Mar 4, 2026ResultsReleased financial results. Filing
  14. Mar 2, 2026AnnouncementEyePoint, Inc. issued a press release announcing the first patients dosed in both COMO and CAPRI, the Company's Phase 3 clinical trials of DURAVYU TM, formerly EYP-1901, for the treatment of diabetic macular edema. Filing
  15. Jan 7, 2026ResultsReleased financial results. Filing
  16. Dec 8, 2025RulesChanged its bylaws or articles. Filing
  17. Nov 19, 2025AnnouncementEyePoint Pharmaceuticals, Inc. issued a press release announcing a positive recommendation from the independent Data Safety Monitoring Committee following completion of its second scheduled review of the Company’s ongoing pivotal Phase 3 program evaluating DURAVYU ™ for the treatment of wet… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

EyePoint financials

Famous investors that hold EYPT

3 of the 50 well-known investors we track reported holding EYPT in their latest 13F filing. The largest position is Israel Englander's, worth $6.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20262.07M$6.8M0.0%+314%
Ken Griffin · Citadel AdvisorsQ3 20262.00M$6.5M0.0%+1%
Paul Tudor Jones · Tudor Investment CorpQ3 202621,942$71.8K0.0%+31%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named EYPT in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Commodore Capital LP13G/A0.0%
Nov 16, 2026Cormorant Asset Management, LP13G/A6.7%
Nov 16, 2026Cormorant Asset Management, LP13G/A6.7%
Nov 16, 2026Commodore Capital LP13G/A0.0%
Nov 4, 2026Federated Hermes, Inc.13G/A1.6%
Nov 4, 2026Federated Hermes, Inc.13G/A1.6%
Oct 30, 2026Vanguard Capital Management13G/A5.0%
Oct 30, 2026Vanguard Capital Management13G/A5.0%
Oct 27, 2026TANG CAPITAL MANAGEMENT, LLC13G9.6%
Oct 27, 2026TANG CAPITAL MANAGEMENT, LLC13G9.6%
Oct 7, 2026Federated Hermes, Inc.13G/A8.0%
Oct 7, 2026Federated Hermes, Inc.13G/A8.0%

Questions about EyePoint, Inc. (EYPT) stock

Who owns the most EYPT stock?

The largest reported owner of EyePoint, Inc. (EYPT) is Montanova Capital, LLC, with 9.9% of the company. In total, 188 funds and institutions reported holding EYPT at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are EYPT insiders buying or selling?

In the last 12 months, EYPT insiders reported 2 open-market purchases worth $72K and 10 sales worth $2M. The latest trade was on Aug 18, 2026. See every trade.

What is the short interest in EYPT?

As of Oct 30, 2026, 11.02M EYPT shares were sold short, 12.8% of the shares outstanding, down 48.2% from the report before. At the average daily volume of 29.80M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold EYPT?

3 of the 50 well-known investors we track reported EYPT in their latest 13F filing, including Israel Englander, Ken Griffin, Paul Tudor Jones. The largest position is worth $6.8M. See all holders.

Executive pay

EyePoint's chief executive was paid a total of $5.6M for the year ended Dec 31, 2025. In the last 12 months, EyePoint's executives and directors bought $72K of stock on the open market and sold $1.1M.

Chief executive, total pay$5.6MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$14MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.